Cargando…
Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic
Patients with pre-existing cardiovascular disease and risk factors are more likely to experience adverse outcomes associated with the novel coronavirus disease-2019 (COVID-19). Additionally, consistent reports of cardiac injury and de novo cardiac complications, including possible myocarditis, arrhy...
Autores principales: | Ganatra, Sarju, Dani, Sourbha S., Shah, Sachin, Asnani, Aarti, Neilan, Tomas G., Lenihan, Daniel, Ky, Bonnie, Barac, Ana, Hayek, Salim S., Leja, Monika, Herrmann, Joerg, Thavendiranathan, Paaladinesh, Fradley, Michael, Bang, Vigyan, Shreyder, Katherine, Parikh, Rohan, Patel, Rushin, Singh, Amitoj, Brar, Simarjeet, Guha, Avirup, Gupta, Dipti, Mascari, Paolo, Patten, Richard D., Venesy, David M., Nohria, Anju, Resnic, Frederic S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255720/ https://www.ncbi.nlm.nih.gov/pubmed/32474135 http://dx.doi.org/10.1016/j.tcm.2020.05.004 |
Ejemplares similares
-
Impact of Social Vulnerability on Comorbid Cancer and Cardiovascular Disease Mortality in the United States
por: Ganatra, Sarju, et al.
Publicado: (2022) -
Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
por: Ganatra, Sarju, et al.
Publicado: (2019) -
Safety and efficacy of transcatheter edge-to-edge repair (TEER) in patients with history of cancer
por: Khan, Sahoor, et al.
Publicado: (2022) -
Cardiotoxicity of Immune Checkpoint Inhibitors
por: Patel, Rushin P., et al.
Publicado: (2021) -
Cardiotoxicity of Contemporary Anticancer Immunotherapy
por: Dal’bo, Natalie, et al.
Publicado: (2020)